MedTrace Logo

Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases

NCT02185443 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2024-12-09

No results posted yet for this study

Summary

This is a Phase II study to determine the efficacy of SBRT to treat liver metastases in patients with Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors that are not amenable to surgery. Patients should have no evidence of extra-hepatic disease or have disease that is planned to be treated with curative intent.

Therefore, SBRT is being considered as a potentially curative procedure.

Conditions

  • Liver Metastases
  • Colorectal Cancer
  • Anal Canal Cancer
  • Gastrointestinal Neuroendocrine Tumors

Interventions

RADIATION

SBRT

* 60Gy in 3 fractions (20Gy/fraction) over 14 days * 60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above

Sponsors & Collaborators

  • Instituto do Cancer do Estado de São Paulo

    collaborator OTHER

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Andre TC Chen, MD, PhD · Instituto do Cancer do Estado de Sao Paulo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02185443 on ClinicalTrials.gov